Table IV.

Univariate and multivariate analysis in the validation cohort.

	Univariate		Multivariate
Variable	OR value (95% CI)	P-value	OR value (95% CI)	P-value
Age (≤65 vs. >65 years)	1.80 (0.58–5.58)	0.304
Sex (male vs. female)	1.03 (0.39–2.73)	0.951
CEA prior to treatment (≤5 vs. >5 µg/l)	1.64 (0.66–4.10)	0.286
Clinical T stage (T2 vs. >T3-4)	1.10 (0.36–3.23)	0.862
Clinical N stage (N0 vs. N1-2)	1.75 (0.46–6.72)	0.411
Tumor size (≤5 vs. >5 cm)	0.80 (0.31–2.10)	0.650
Tumor circumference (≤50 vs. >50%)	0.51 (0.20–1.26)	0.140
Mesorectal fascia (negative vs. positive)	1.24 (0.48–3.21)	0.665
Distance from anal verge (≤5 vs. >5 cm)	0.84 (0.33–2.16)	0.722
Tumor differentiation (low vs. medium, high)	0.33 (0.08–1.45)	0.023	0.32 (0.07–1.55)	0.157
Operation interval of radiotherapy (≤7 vs. >7 weeks)	1.97 (0.70–5.54)	0.194
Chemotherapy regimens (with oxaliplatin vs. without oxaliplatin)	3.06 (0.95–9.87)	0.054	2.18 (0.64–7.47)	0.213
Chemotherapy course (≤4 vs. >4 courses)	1.76 (0.53–5.84)	0.348
Percentage change in NLR (≤21.5 vs. >21.5%)	0.34 (0.13–0.85)	0.019	0.34 (0.13–0.90)	0.030

CEA, carcino-embryonic antigen; T, tumor; N, lymph node; NLR, neutrophil-to-lymphocyte ratio; OR, odds ratio; CI, confidence interval.